Results of the phase III MIDAS study, conducted at the Universite de Toulouse in France, with findings reported at the American Society of Clinical Oncology (ASCO) Annual Meeting, indicated that newly diagnosed multiple myeloma patients "and a postinduction measurable residual disease (MRD)-negative status...consolidation therapy with autologous stem-cell transplantation...compared with isatuximab, carfilzomib, lenalidomide, and dexamethasone...did not lead to a significant difference in percentage of patients who were MED-negative...before maintenance therapy." Further, the authors of the study emphasized challenges of treating myeloma patients, especially with regards to implementing an effective risk-adapted therapeutic strategy.
To read more about the MIDAS study, click here.
Source mentioned:
- Perrot A, Lambert J, Hulin C, et al. for the MIDAS Study Group. Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma . NEJM; Published online 3 June 2025. DOI: 10.1056/NEJMoa2505133
- Perrot A, Hulin C, Lambert J, et al. MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial . J Clin Oncol 2025;43(suppl 16):abstr LBA7500. DOI: 10.1200/JCO.2025.43.16_suppl.7500
No comments:
Post a Comment